文献速递细胞病理与分子病理

意义未明的不典型增生(AUS)在甲状腺细胞学中的质量指标探索

Exploring the atypia of undetermined significance: Malignant ratio, ThyroSeq v3 positive call rate, molecular-derived risk of malignancy, and risk of malignancy as possible quality metric tools in thyroid cytology.
PubMed 文献 · Cancer Cytopathol · 2024-04-09

该研究回顾了2022年8月至2023年9月间7位细胞病理学家评估的2248例甲状腺穿刺标本,计算AUS与恶性(AUS:M)比值、ThyroSeq v3阳性报告率(PCR)、分子衍生恶性风险(MDROM)及恶性风险(ROM)。实验室整体AUS:M比值为5.8(个体范围2.8-7.3),TSV3 PCR为23%(11%-41%),MDROM为19%(9%-31%),ROM为36%(29%-50%)。AUS:M比值与TSV3 PCR及MDROM呈中度正相关,与ROM呈弱负相关。结论强调联合多种指标评估诊断实践并提供个体化反馈的重要性。

要点

  • AUS:M比值、TSV3 PCR和MDROM可作为评估AUS使用质量的工具。
  • 实验室整体AUS:M比值5.8,个体范围2.8-7.3,需结合其他指标解读。
  • AUS:M比值与TSV3 PCR和MDROM中度正相关,与ROM弱负相关。

核心结论

  • 联合使用AUS:M比值、TSV3 PCR、MDROM和ROM等多种指标有助于全面评估细胞病理学家的诊断实践。
  • 通过分析每位细胞病理学家的实践模式,可测量其不同方面的表现并提供个体化反馈。

研究设计与样本

  • 回顾性研究,纳入2022年8月至2023年9月实验室评估的甲状腺穿刺标本,由7位细胞病理学家判读。
  • 共识别2248例穿刺标本,其中462例为AUS,80例为恶性。

主要发现

  • 实验室整体AUS:M比值为5.8,细胞病理学家个体范围2.8至7.3。
  • 实验室整体TSV3 PCR为23%,个体范围11%至41%。
  • 实验室整体MDROM为19%,个体范围9%至31%;ROM为36%,个体范围29%至50%。
  • 线性回归分析显示AUS:M比值与TSV3 PCR及MDROM呈中度正相关,与ROM呈弱负相关。

关键数值与推荐

  • AUS率建议≤10%以预防过度使用,但该建议缺乏支持数据。
  • AUS:M比值、TSV3 PCR、MDROM和ROM被提出作为质量指标工具。

临床怎么用

  • 病理科可联合采用AUS:M比值、TSV3 PCR、MDROM和ROM等指标监测AUS使用情况。
  • 针对每位细胞病理学家的指标偏离,可分析多因素原因并提供个体化反馈以改进诊断质量。

局限性

  • 偏离既定目标的原因归因于多种因素,但原文未具体说明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The atypia of undetermined significance (AUS) category is heterogeneous, leading to variations in its use. To prevent excessive usage, the AUS rate should be ≤10%. Although this recommendation aims to maintain diagnostic quality, it lacks supporting data. The AUS:Malignant (AUS:M) ratio has been proposed as a metric tool to evaluate AUS use. Furthermore, integrating ThyroSeq v3 (TSV3) positive call rate (PCR) and the molecular-derived risk of malignancy (MDROM) have been put forward as performance improvement tools. The authors reviewed their AUS:M ratios, TSV3 PCR, MDROM, and ROM. METHODS: Thyroid aspirates evaluated in the laboratory (from August 2022 to September 2023) by seven cytopathologists (CPs) were identified. AUS:M ratio, MDROM, ROM, and TSV3 PCR results for the laboratory and each CP were recorded and analyzed. RESULTS: A total of 2248 aspirates were identified (462 AUS and 80 malignant). The AUS:M ratio for the laboratory was 5.8 (CPs range, 2.8 to 7.3). The TSV3 PCR for the laboratory was 23% (CPs range, 11% to 41%). The MDROM for the laboratory was 19% (CPs range, 9% to 31%), whereas the ROM was 36% (CPs range, 29% to 50%). Linear regression analysis of AUS:M ratio versus TSV3 PCR and MDROM demonstrated a moderate positive correlation but a weak negative correlation to the ROM. Deviations from established targets were attributed to multiple factors. CONCLUSION: The findings of this study underscore the importance of using a combination of metrics to evaluate diagnostic practices. By dissecting the practice patterns of each CP, the authors can measure different aspects of their performance and provide individualized feedback.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Velez Torres JM, Curnow PM, Tjendra Y, et al. Exploring the atypia of undetermined significance: Malignant ratio, ThyroSeq v3 positive call rate, molecular-derived risk of malignancy, and risk of malignancy as possible quality metric tools in thyroid cytology. Cancer Cytopathol. 2024. PMID: 38594180. doi:10.1002/cncy.22820

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。